Literature DB >> 32477467

Correction: JARID1B promotes metastasis and epithelial-mesenchymal transition via PTEN/AKT signaling in hepatocellular carcinoma cells.

Bo Tang1,2, Guangying Qi2,3, Fang Tang1,2, Shengguang Yuan1,2, Zhenran Wang1,2, Xingsi Liang1,2, Bo Li1,2, Shuiping Yu1,2, Jie Liu1,2, Qi Huang1,2, Yangchao Wei1,2, Run Zhai1,2, Biao Lei1,2, Hongping Yu4, Xingyuan Jiao5, Songqing He1,2.   

Abstract

[This corrects the article DOI: 10.18632/oncotarget.3713.]. Copyright:
© 2020 Tang et al.

Entities:  

Year:  2020        PMID: 32477467      PMCID: PMC7233803          DOI: 10.18632/oncotarget.27470

Source DB:  PubMed          Journal:  Oncotarget        ISSN: 1949-2553


This article has been corrected: In Figure 5C, “pBabe’s Migration” was accidentally duplicated as “pcDNA3.1’s Migration” in Figure 8D. The corrected Figure 8D is shown below. The authors declare that these corrections do not change the results or conclusions of this paper.
Figure 8

JARID1B regulates PTEN transcriptional expression through H3K4 trimethylation.

Original article: Oncotarget. 2015; 6:12723–12739. 12723-12739. https://doi.org/10.18632/oncotarget.3713 (A and B), the abundance of H3 lysine methylation was assessed in HCC cells with JARID1B overexpression (A) or silencing (B) by Western blotting using whole-cell lysate; total H3 and β-actin were used as a loading control. (C) schematic presentation of three regions relative to the PTEN transcriptional start site used as primers to test histone occupied abundance. (D and E) qChIP was performed to assess H3K4me3 occupancy in HepG2-pBabe-JARID1B (D), SK-Hep1-pSuper-shJARID1B (E) or their control cells. IgG was used as negative control (D and E, left). “Percentage of input” indicates the ratio of DNA fragment of each promoter region bound by H3K4me3 to the total amount of input DNA fragment without H3K4me3 antibody pull-down. **, P < 0.01 is based on the Student t test. All results are from three independent experiments. Error bars, SD.
  1 in total

1.  A New CYP2E1 Inhibitor, 12-Imidazolyl-1-dodecanol, Represents a Potential Treatment for Hepatocellular Carcinoma.

Authors:  Torsten Diesinger; Alfred Lautwein; Sebastian Bergler; Dominik Buckert; Christian Renz; Radovan Dvorsky; Vyacheslav Buko; Siarhei Kirko; Edith Schneider; Florian Kuchenbauer; Mukesh Kumar; Cagatay Günes; Felicitas Genze; Berthold Büchele; Thomas Simmet; Martin Haslbeck; Kai Masur; Thomas Barth; Dieter Müller-Enoch; Thomas Wirth; Thomas Haehner
Journal:  Can J Gastroenterol Hepatol       Date:  2021-02-02
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.